Hydrocotarnine

Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research[1][2][3].

Product Specifications

CAS Number

[550-10-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

E1/E2/E3 Enzyme; Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hydrocotarnine.html

Purity

99.70

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CN1CCC2=CC3=C(C(=C2C1)OC)OCO3

Molecular Formula

C12H15NO3

Molecular Weight

221.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Chung IC, et al. Src-family kinase-Cbl axis negatively regulates NLRP3 inflammasome activation. Cell Death Dis. 2018 Oct 31;9 (11) :1109. |[2]Lin HC, et al. Cbl Negatively Regulates NLRP3 Inflammasome Activation through GLUT1-Dependent Glycolysis Inhibition. Int J Mol Sci. 2020 Jul 19;21 (14) :5104. |[3]Kim KU, et al. DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1. Eur J Pharmacol. 2019 Mar 15;847:113-122.